TORONTO, Dec. 7, 2017 /PRNewswire/ — Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced that the Company has begun applying machine learning to its large and growing trove of patient data to develop algorithms capable of delivering patient insights on diagnosis and treatment plans for clinicians, into Ehave’s flagship cloud-based informatics platform.  These new capabilities will eventually be offered alongside the integrated gold-standard psychological assessment tools for mental healthcare and digital intake of medical cannabis patients that are offered in Ehave Connect, the company’s digital marketplace of diagnostic and treatment tools.

As the Ehave Platform continues to collect and integrate patient data from clinical systems, licensed mental health surveys, and Ehave’s own patient and clinician reported outcome applications, this new capability is currently being developed using a state of the art, end-to-end machine learning service. Ehave intends to provide data scientists and researchers access to these same tools and services to build, train, and host their own artificial intelligence services.

Prateek Dwivedi, CEO of Ehave, said, “As we ramp up our capabilities in artificial intelligence and machine learning, we begin to demonstrate the true capabilities of the Ehave Platform. Our platform goes beyond our best-in-class data management system to provide mental health practitioners with supplemental diagnosis data based on scoring results of multiple gold standard psychological assessments. Physicians trying to understand which medical cannabis strains will be most effective to prescribe for their patients will be provided with comparative data on the dose, frequency and route of delivery of cannabis therapy.”

About Ehave, Inc.
Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. For more information, visit https://www.ehave.com/.

Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Contacts
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (Investors)
(212) 375-2664
jdrumm@tiberend.com

Janine McCargo (Media)
646-604-5150
jmccargo@tiberend.com

View original content:http://www.prnewswire.com/news-releases/ehave-announces-deployment-of-machine-learning-to-deliver-patient-insights-for-mental-healthcare-and-medical-cannabis-300568251.html

SOURCE Ehave, Inc.